Antimicrobial Agents Practice Questions

Q: Which drug can cause complete histopathological resolution in patients with hepatitis B?

Entecavir. **Explanation:** **Entecavir** is a potent deoxyguanosine nucleoside analog that inhibits Hepatitis B Virus (HBV) polymerase at three stages: priming, reverse transcription, and synthesis of the positive-strand DNA. It is considered a first-line treatment for chronic HBV due to its high genetic barrier to resistance and superior efficacy. Clinical studies have demonstrated that long-term therapy with Entecavir leads to significant **histological improvement**, including the reduction of necroinflammatory activity and, crucially, the **reversal of fibrosis and cirrhosis** (complete histopathological resolution) in a majority of patients. **Why other options are incorrect:** * **Cyclosporin:** This is a calcineurin inhibitor used as an immunosuppressant. While it has some *in vitro* activity against certain viruses by inhibiting cyclophilins, it is not used to treat HBV and can actually exacerbate viral replication by suppressing the host immune response. * **Ribavirin:** This is a guanosine analog used primarily for Hepatitis C (in combination with Interferon or DAAs) and RSV. It has no significant clinical efficacy against the Hepatitis B virus. **High-Yield Clinical Pearls for NEET-PG:** * **First-line HBV drugs:** Entecavir and Tenofovir (TDF/TAF) are preferred due to low resistance rates. * **Mechanism:** Entecavir requires intracellular phosphorylation to the active triphosphate form. * **Safety:** Entecavir is generally well-tolerated but requires dose adjustment in renal impairment. Unlike Tenofovir, it is not associated with significant bone or renal toxicity. * **Lamivudine Resistance:** Patients with prior Lamivudine resistance have a higher risk of developing resistance to Entecavir.

Q: Which drug does NOT inhibit nucleic acid synthesis?

Linezolid. ### Explanation The correct answer is **Linezolid**. To solve this question, one must categorize antimicrobial agents based on their primary mechanism of action: inhibition of cell wall synthesis, protein synthesis, or nucleic acid synthesis. **1. Why Linezolid is the correct answer:** Linezolid belongs to the **Oxazolidinone** class. Its primary mechanism is the **inhibition of protein synthesis**. Specifically, it binds to the 23S ribosomal RNA of the **50S subunit**, preventing the formation of the 70S initiation complex. Because it acts on protein translation rather than DNA/RNA replication or transcription, it does not inhibit nucleic acid synthesis. **2. Why the other options are incorrect:** * **Rifampicin:** Inhibits **DNA-dependent RNA polymerase**, thereby blocking the synthesis of mRNA (transcription). * **Fluoroquinolones (e.g., Ciprofloxacin):** Inhibit **DNA Gyrase (Topoisomerase II)** and **Topoisomerase IV**, preventing DNA replication and transcription. * **Nitrofurantoin:** This drug is reduced by bacterial flavoproteins to reactive intermediates that **damage bacterial DNA** and inhibit various enzymes involved in nucleic acid metabolism. **Clinical Pearls for NEET-PG:** * **Linezolid Spectrum:** It is a "reserve drug" primarily used for Gram-positive infections, including **MRSA** (Methicillin-resistant *Staph. aureus*) and **VRE** (Vancomycin-resistant *Enterococci*). * **Side Effects of Linezolid:** Long-term use can cause **thrombocytopenia** (bone marrow suppression) and **optic/peripheral neuropathy**. * **Drug Interaction:** Linezolid is a weak non-selective **MAO inhibitor**; it can cause **Serotonin Syndrome** if co-administered with SSRIs. * **Mnemonic for Protein Synthesis Inhibitors:** "**Buy AT 30, CELL at 50**" (Aminoglycosides, Tetracyclines act on 30S; Chloramphenicol, Erythromycin/Macrolides, Linezolid, Lincosamides act on 50S).

Q: Which anti-HIV drug combination should not be used?

All of the above. **Explanation:** The correct answer is **D (All of the above)** because these combinations result in either pharmacological antagonism or additive toxicities, making them clinically inappropriate. **1. Zidovudine (AZT) + Stavudine (d4T):** This is a classic example of **pharmacological antagonism**. Both drugs are thymidine analogs that require intracellular phosphorylation by the same enzyme, **thymidine kinase**, to become active. Zidovudine has a higher affinity for this enzyme and competitively inhibits the activation of Stavudine, rendering the combination ineffective. **2. Atazanavir + Indinavir:** Both are Protease Inhibitors (PIs). Combining them is avoided because they share a similar toxicity profile, specifically **hyperbilirubinemia** (indirect). Using them together significantly increases the risk of severe jaundice and nephrolithiasis without providing additional antiviral synergy. **3. Didanosine/Stavudine + Zalcitabine:** These combinations are contraindicated due to **overlapping toxicities**. All three are Nucleoside Reverse Transcriptase Inhibitors (NRTIs) that can cause severe **peripheral neuropathy** and **pancreatitis**. Furthermore, the combination of Stavudine and Didanosine is specifically linked to a high risk of fatal lactic acidosis, especially in pregnant women. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for Peripheral Neuropathy (NRTIs):** The "3 Ds" – Didanosine, Zalcitabine (ddC), and Stavudine (d4T). * **Zidovudine** is known for causing **bone marrow suppression** (anemia/neutropenia). * **Abacavir** is associated with hypersensitivity reactions linked to the **HLA-B*5701** allele. * **Tenofovir** is the NRTI most commonly associated with **renal toxicity** (Fanconi syndrome) and decreased bone mineral density [1].

Q: What is the most effective antitubercular drug against slow multiplying intracellular mycobacteria?

Pyrazinamide. ### Explanation The correct answer is **Pyrazinamide (Option C)**. #### Why Pyrazinamide is Correct Mycobacterium tuberculosis populations are heterogeneous. Pyrazinamide is uniquely effective against **slowly multiplying intracellular bacilli** located within the acidic environment of macrophages (phagosomes). * **Mechanism:** It is a prodrug converted by the bacterial enzyme **pyrazinamidase** into **pyrazinoic acid**. This conversion occurs most efficiently at an acidic pH. * **Sterilizing Action:** Because it targets the "persisters" (dormant bacilli) that other drugs cannot reach, it possesses the highest **sterilizing activity**. This unique property allowed the duration of TB treatment to be shortened from 9 months to 6 months. #### Why Other Options are Incorrect * **Rifampicin (Option A):** While it is a potent bactericidal drug, it is most effective against **spurters** (bacilli that undergo occasional bursts of metabolic activity). It is considered the best sterilizing agent overall but is not as specific for the acidic intracellular niche as Pyrazinamide. * **Isoniazid (Option B):** It is the most potent bactericidal drug against **rapidly multiplying extracellular bacilli** (found in the walls of cavitary lesions). It has poor activity against slow-growers. * **Ethambutol (Option D):** It is primarily **bacteriostatic** and is used to prevent the emergence of resistance to other drugs. It does not have significant sterilizing activity against dormant bacilli. #### NEET-PG High-Yield Pearls * **Site of Action:** Pyrazinamide = Acidic pH (Intracellular); Streptomycin = Alkaline pH (Extracellular). * **Toxicity:** Pyrazinamide is the **most hepatotoxic** of the first-line drugs and commonly causes **hyperuricemia** (due to inhibition of uric acid excretion), which may precipitate gout. * **Resistance:** Mutation in the **pncA gene** (encoding pyrazinamidase) is the most common cause of resistance.

Q: Which of the following antimicrobials needs dose reduction even in mild renal failure?

Ethambutol. **Explanation:** The correct answer is **Ethambutol**. **1. Why Ethambutol is correct:** Ethambutol is primarily excreted unchanged by the kidneys (approx. 80%). It has a narrow therapeutic index regarding ocular toxicity (optic neuritis). In renal impairment, the drug accumulates rapidly, significantly increasing the risk of irreversible vision loss. Current guidelines recommend that even in **mild renal failure** (CrCl < 70-100 ml/min), the dose should be monitored, and if CrCl falls below 30 ml/min, the dosing interval must be increased to 3 times weekly rather than daily. **2. Why the other options are incorrect:** * **Ciprofloxacin:** While it is renally excreted, dose reduction is typically only required in **moderate to severe** renal failure (CrCl < 30-50 ml/min). * **Carbenicillin:** This is an antipseudonal penicillin. While it requires adjustment in renal failure to prevent seizures and bleeding diathesis, it has a wider safety margin than ethambutol in mild cases. * **Cefotaxime:** Most cephalosporins have a high therapeutic index. Cefotaxime requires dose adjustment only when the GFR drops below 20 ml/min (**severe** impairment). **3. NEET-PG High-Yield Pearls:** * **Ethambutol Toxicity:** The most characteristic side effect is **retrobulbar neuritis**, resulting in decreased visual acuity and **red-green color blindness**. It is contraindicated in children too young to undergo visual testing. * **Safe in Renal Failure:** Antibiotics like **Ceftriaxone, Doxycycline, Erythromycin, and Rifampicin** are primarily eliminated via the liver/bile and generally do not require dose adjustment in renal failure. * **Rule of Thumb:** Always prioritize dose adjustment for drugs with narrow therapeutic windows (Aminoglycosides, Vancomycin, Ethambutol, Lithium) in renal patients.

Q: Which anti-tuberculosis drug leads to resistance most rapidly?

Isoniazid. **Explanation:** The development of drug resistance in *Mycobacterium tuberculosis* occurs due to spontaneous genetic mutations. Among the first-line anti-tubercular drugs (ATT), **Isoniazid (INH)** is associated with the most rapid development of resistance when used as monotherapy. **Why Isoniazid is the correct answer:** Resistance to INH occurs primarily due to mutations in the **katG gene**, which encodes the enzyme **catalase-peroxidase**. Since INH is a prodrug, it requires this enzyme for activation. A single-step mutation in katG leads to a high level of resistance. Statistically, the frequency of spontaneous mutations for INH is approximately **1 in 10⁶** bacilli, which is significantly higher than for other drugs like Rifampicin. **Analysis of Incorrect Options:** * **Rifampicin:** Resistance develops due to mutations in the **rpoB gene** (beta-subunit of RNA polymerase). The mutation frequency is much lower (**1 in 10⁸**), making it less likely to develop resistance as rapidly as INH. * **Streptomycin:** Resistance occurs via mutations in the **rpsL or rrs genes** (ribosomal proteins). While resistance can develop, it is generally slower and less frequent than INH in a clinical population. * **Ethambutol:** Resistance develops due to mutations in the **embB gene** (arabinosyl transferase). It is a bacteriostatic drug with a relatively low rate of primary resistance compared to INH. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of Action:** INH inhibits **Mycolic acid synthesis**; Rifampicin inhibits **DNA-dependent RNA polymerase**. * **MDR-TB Definition:** Resistance to at least **Isoniazid and Rifampicin**. * **XDR-TB Definition:** MDR-TB plus resistance to any **Fluoroquinolone** and at least one **second-line injectable** (Amikacin, Kanamycin, or Capreomycin). * **Prophylaxis:** INH is the drug of choice for latent TB and chemoprophylaxis in HIV-positive patients or household contacts of open TB cases.

Q: A 30-year-old pregnant woman develops tuberculosis. Which of the following antitubercular drugs should not be used?

Streptomycin. **Explanation:** The correct answer is **Streptomycin** because it is a member of the aminoglycoside class, which is known to be **ototoxic and nephrotoxic**. In pregnancy, Streptomycin crosses the placental barrier and can cause **permanent bilateral congenital deafness** (CN VIII damage) in the fetus. Consequently, it is classified as FDA Pregnancy Category D and is generally contraindicated unless no other alternatives exist. **Analysis of Options:** * **Isoniazid (INH):** Considered safe in pregnancy. However, due to the increased risk of peripheral neuropathy in pregnant women, it must be co-administered with **Pyridoxine (Vitamin B6)**. * **Rifampicin:** Considered safe and is a core component of the RNTCP/WHO regimen for pregnant women. It has no documented teratogenic effects in humans at standard doses. * **Ethambutol:** Considered the safest of the first-line antitubercular drugs during pregnancy; it does not cross the placenta in significant amounts to cause fetal ocular toxicity. **NEET-PG High-Yield Pearls:** 1. **Standard Regimen:** The WHO and National Guidelines recommend the standard 6-month 2HRE/4HR regimen for pregnant women. **Pyrazinamide** is also now considered safe and included in the intensive phase. 2. **Vitamin B6:** Always supplement INH with 10–25 mg/day of Pyridoxine in pregnancy to prevent maternal neuropathy and fetal seizures. 3. **Contraindicated Drugs:** Avoid **Streptomycin** (Ototoxicity), **Ethionamide** (Teratogenic), and **Fluoroquinolones** (Cartilage damage/Arthropathy) during pregnancy. 4. **Breastfeeding:** All first-line ATT drugs are compatible with breastfeeding as they occur in negligible concentrations in breast milk.

Q: Which of the following drugs used for chronic hepatitis B therapy is not administered orally?

Pegylated interferon. The management of Chronic Hepatitis B (CHB) involves two main classes of drugs: **Nucleos(t)ide Analogues (NAs)** and **Immunomodulators**. **1. Why Pegylated Interferon (Peg-IFN) is correct:** Pegylated interferon-alpha (2a or 2b) is a protein-based immunomodulator. Because it is a protein, it would be degraded by gastric enzymes if taken orally. Therefore, it must be administered via **subcutaneous injection** (usually once weekly) [1]. It works by enhancing the host immune response and exerting direct antiviral effects. **2. Why the other options are incorrect:** * **Lamivudine (A):** A nucleoside analogue that inhibits HBV DNA polymerase. It was the first oral agent approved for HBV. * **Adefovir (B):** A nucleotide analogue administered orally. It is now less commonly used due to its lower potency and risk of nephrotoxicity compared to newer agents. * **Telbivudine (C):** An oral L-nucleoside analogue. Like Lamivudine, it has a high rate of resistance, leading to its decreased use in modern clinical practice. **Clinical Pearls for NEET-PG:** * **First-line Oral Agents:** Currently, **Tenofovir (TDF/TAF)** and **Entecavir** are the preferred oral agents due to their high potency and high genetic barrier to resistance. * **Interferon Contraindications:** Peg-IFN should be avoided in patients with decompensated cirrhosis, psychiatric disorders, or autoimmune diseases [1]. * **HBeAg Seroconversion:** Peg-IFN has a higher rate of HBeAg and HBsAg clearance compared to oral NAs but is associated with more side effects (flu-like symptoms, bone marrow suppression) [1]. * **Pregnancy:** Tenofovir is the preferred agent for preventing vertical transmission in highly viremic mothers.

Q: Which of the following drugs is not used in the treatment of multibacillary leprosy as per the recommendations of the World Health Organization?

Minocycline. **Explanation:** The World Health Organization (WHO) recommends a standardized **Multi-Drug Therapy (MDT)** regimen for the treatment of leprosy to prevent the emergence of drug resistance. **Why Minocycline is the correct answer:** While Minocycline possesses significant bactericidal activity against *Mycobacterium leprae*, it is considered a **second-line drug**. It is not part of the standard WHO-recommended MDT for Multibacillary (MB) leprosy. It is primarily used in alternative regimens for patients who cannot tolerate first-line drugs or in the ROM (Rifampicin, Ofloxacin, Minocycline) regimen for Single Lesion Paucibacillary leprosy. **Analysis of incorrect options:** * **A. Rifampicin:** The most potent bactericidal component of the MDT. In MB leprosy, it is administered as a supervised monthly dose of 600 mg. * **B. Clofazimine:** A dye with weak bactericidal and anti-inflammatory properties. It is essential in MB leprosy to prevent the development of Erythema Nodosum Leprosum (ENL) and is given as a 300 mg monthly supervised dose and 50 mg daily self-administered dose. * **C. Dapsone:** A bacteriostatic drug that inhibits folate synthesis. It is a core component of the MDT, administered as a 100 mg daily dose. **High-Yield Clinical Pearls for NEET-PG:** * **WHO MB-MDT Regimen:** Rifampicin (600mg/month), Clofazimine (300mg/month + 50mg/day), and Dapsone (100mg/day) for a total duration of **12 months**. * **Uniform MDT (U-MDT):** Recent WHO guidelines suggest a 6-month regimen of the same three drugs for both PB and MB leprosy to simplify logistics. * **Side Effects:** Clofazimine causes brownish-black skin discoloration; Dapsone can cause hemolysis (especially in G6PD deficiency) and "Dapsone Syndrome."

Q: Which antibiotic can be safely administered to pregnant women?

Cefuroxime. **Explanation:** The safety of drugs during pregnancy is categorized by the FDA. The correct answer is **Cefuroxime**, a second-generation cephalosporin. **1. Why Cefuroxime is correct:** Cephalosporins (along with Penicillins and Erythromycin) are classified as **FDA Category B**. They do not have documented teratogenic effects in humans and are considered the "drugs of choice" for treating bacterial infections during pregnancy. Cefuroxime is safe for treating respiratory tract infections and UTIs in pregnant patients. **2. Why the other options are incorrect:** * **Ciprofloxacin (Option A):** This is a Fluoroquinolone. These are generally avoided in pregnancy because they have a high affinity for bone and cartilage, potentially causing **arthropathy** and permanent cartilage damage in the developing fetus. * **Metronidazole (Option C):** While often used after the first trimester for specific indications, it is traditionally avoided in the **first trimester** due to theoretical concerns regarding mutagenicity (though human data is reassuring, it remains less "safe" than Cephalosporins). * **Chloramphenicol (Option D):** It is contraindicated, especially near term. It can lead to **Gray Baby Syndrome** in neonates because their immature livers cannot conjugate the drug via glucuronidation, leading to toxic accumulation and cardiovascular collapse. **Clinical Pearls for NEET-PG:** * **Safe Antibiotics (CAMP):** **C**ephalosporins, **A**moxicillin/Ampicillin, **M**acrolides (except Estolate form), and **P**enicillins. * **Teratogenic Antibiotics to remember:** * **Tetracyclines:** Discolored teeth and inhibited bone growth. * **Aminoglycosides:** Ototoxicity (CN VIII damage). * **Sulfonamides:** Kernicterus (if given near term). * **Nitrofurantoin:** Hemolysis if the fetus is G6PD deficient.

Question 1

Which drug can cause complete histopathological resolution in patients with hepatitis B?

Accepted Answer

Entecavir

Answer

Cyclosporin

Answer

Ribavirin

Answer

None of the above

Question 2

Which drug does NOT inhibit nucleic acid synthesis?

Accepted Answer

Linezolid

Answer

Rifampicin

Answer

Fluoroquinolone

Answer

Nitrofurantoin

Question 3

Which anti-HIV drug combination should not be used?

Accepted Answer

All of the above

Answer

Zidovudine + Stavudine

Answer

Atazanavir + Indinavir

Answer

Didanosine/stavudine + Zalcitabine

Question 4

What is the most effective antitubercular drug against slow multiplying intracellular mycobacteria?

Accepted Answer

Pyrazinamide

Answer

Rifampicin

Answer

Isoniazid

Answer

Ethambutol

Question 5

Which of the following antimicrobials needs dose reduction even in mild renal failure?

Accepted Answer

Ethambutol

Answer

Ciprofloxacin

Answer

Carbenicillin

Answer

Cefotaxime

Question 6

Which anti-tuberculosis drug leads to resistance most rapidly?

Accepted Answer

Isoniazid

Answer

Streptomycin

Answer

Rifampicin

Answer

Ethambutol

Question 7

A 30-year-old pregnant woman develops tuberculosis. Which of the following antitubercular drugs should not be used?

Accepted Answer

Streptomycin

Answer

Isoniazid (INH)

Answer

Rifampicin

Answer

Ethambutol

Question 8

Which of the following drugs used for chronic hepatitis B therapy is not administered orally?

Accepted Answer

Pegylated interferon

Answer

Lamivudine

Answer

Adefovir

Answer

Telbivudine

Question 9

Which of the following drugs is not used in the treatment of multibacillary leprosy as per the recommendations of the World Health Organization?

Accepted Answer

Minocycline

Answer

Rifampicin

Answer

Clofazimine

Answer

Dapsone

Question 10

Which antibiotic can be safely administered to pregnant women?

Accepted Answer

Cefuroxime

Answer

Ciprofloxacin

Answer

Metronidazole

Answer

Chloramphenicol

Antimicrobial Agents — MCQs

Antimicrobial Agents — MCQs

On this page

Practice by Chapter

Want unlimited practice?